Get the Stockscreener App
23.26
0.43%
0.0536
Dyne Therapeutics Inc stock is traded at $23.26, with a volume of 1.30M.
It is up +0.43% in the last 24 hours and up +15.06% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$23.21
Open:
$22.95
24h Volume:
1.30M
Relative Volume:
0.69
Market Cap:
$3.84B
Revenue:
-
Net Income/Loss:
$-451.71M
P/E Ratio:
-7.2111
EPS:
-3.2261
Net Cash Flow:
$-462.19M
1W Performance:
+2.60%
1M Performance:
+15.06%
6M Performance:
+29.50%
1Y Performance:
+148.51%
1-Day Range:
$22.75
$24.34
1-Week Range:
$21.71
$24.79
52-Week Range:
$8.88
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
23.23 | 3.84B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
474.79 | 119.94B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
650.21 | 68.27B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
905.02 | 53.28B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.69 | 38.91B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
265.44 | 35.65B | 4.29B | 577.22M | 641.34M | 4.2086 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Cantor Fitzgerald initiates Dyne Therapeutics stock with overweight rating By Investing.com - Investing.com Canada
Dyne Therapeutics (DYN) Prices Upsized Share Offering, Is The Valuation Still Compelling? - Yahoo Finance
Form 424B5 Dyne Therapeutics Inc For: 22 July By Investing.com - Investing.com South Africa
Dyne Therapeutics Launches 18.3M-Share Offering at $20.50; Nets ~$352M, Greenshoe to $405M - TradingView
Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN) - MSN
Why Dyne Therapeutics (DYN) Stock Is Down Today - Moomoo
Dyne Therapeutics (DYN) Upsizes Public Offering to $375.15M Amid Stock Decline - GuruFocus
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat? - The Globe and Mail
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower - Benzinga
Why is Dyne Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Dyne Therapeutics stock falls 9% after pricing stock offering By Investing.com - Investing.com Australia
Dyne Therapeutics stock falls 9% after pricing stock offering - Investing.com UK
Dyne Therapeutics Prices Upsized $375.2 Million Secondary Offering - marketscreener.com
Form 424B5 Dyne Therapeutics Inc For: 21 July By Investing.com - Investing.com South Africa
Dyne Therapeutics Stock Tumbles After Hours: Here's Why - Benzinga
Form 424B5 Dyne Therapeutics Inc For: 21 July - Investing.com India
DYN: Increased Offering Size and Pricing Range Announced - GuruFocus
Dyne Therapeutics prices $375 million stock offering - Investing.com
Dyne Therapeutics prices $375 million stock offering By Investing.com - Investing.com South Africa
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock - The Manila Times
Dyne Therapeutics prices $375M upsized public o... - Pluang
Dyne Therapeutics,Announces Pricing Of Upsized Offering Of 18.3 Million Shares At $20.50 Per Share - TradingView
Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock - Stocktwits
Stocks to Watch: Super Micro Computer, AAR, Pegasystems, Dyne Therapeutics, Weatherford - Moomoo
Shares of Dyne Therapeutics Slide on $300M Stock Offering - Moomoo
Dyne Therapeutics Launches $300 Million Common Stock Offering - Moomoo
Dyne Therapeutics launches $300 million stock offering By Investing.com - Investing.com Nigeria
Dyne Therapeutics stock falls on $300M equity offering - Investing.com
Dyne Therapeutics Announces Proposed Public Offering of Common Stock - The Manila Times
Dyne Therapeutics stock falls on $300M equity offering By Investing.com - Investing.com Nigeria
Dyne Therapeutics Announces $300 Million Proposed Public Offering of Common Stock - Quiver Quantitative
Dyne Therapeutics Announces Proposed Public Offering Of Common Stock - TradingView
Press Release: Dyne Therapeutics Announces Proposed Public Offering of Common Stock - Moomoo
Should FDA Priority Review of Dyne’s DMD Drug Candidate Reshape Risk Expectations for Dyne Therapeutics (DYN) Investors? - simplywall.st
Dyne Therapeutics, Inc. (DYN): Investor Outlook on a Biotech Pioneer with 67% Upside Potential - DirectorsTalk Interviews
Dyne Therapeutics (DYN) Receives FDA Acceptance for Duchenne Tre - GuruFocus
Dyne Therapeutics: A Buy, With Caveats, On DMD Progress (NASDAQ:DYN) - Seeking Alpha
FDA accepts Dyne Duchenne BLA, grants Priority Review - The Pharma Letter
Dyne gets priority review for DMD therapy - grafa.com
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
Dyne Therapeutics (DYN) Sees FDA Acceptance for Key DMD Applicat - GuruFocus
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) - The Manila Times
Dyne's BLA for z-rostudirsen accepted by FDA; Priority Review, PDUFA Jan 21, 2027 - TradingView
Dyne Therapeutics’ z-rostudirsen Accepted for FDA Review with Priority Review Granted for Duchenne Muscular Dystrophy - Quiver Quantitative
Dyne Therapeutics (NASDAQ: DYN) DMD therapy wins FDA Priority Review, PDUFA set - Stock Titan
FDA Sets Jan. 21, 2027 Target Action Date for Dyne's Duchenne Treatment - Stock Titan
Dyne says FDA accepts z-rostudirsen BLA for exon 51 Duchenne muscular dystrophy under priority review - Bitget
symbol__ Stock Quote Price and Forecast - CNN
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dyne Therapeutics Inc Stock (DYN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rhodes Jason P | Director |
Jul 07 '26 |
Sale |
23.26 |
297,211 |
6,913,822 |
2,962 |
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):